{"id":62416,"date":"2026-04-04T23:08:59","date_gmt":"2026-04-04T15:08:59","guid":{"rendered":"https:\/\/flcube.com\/?p=62416"},"modified":"2026-04-04T23:09:00","modified_gmt":"2026-04-04T15:09:00","slug":"zhuhai-rundus-higenamine-receives-nmpa-approval-as-chinas-first-category-1-cardiac-stress-test-agent","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62416","title":{"rendered":"Zhuhai Rundu&#8217;s Higenamine Receives NMPA Approval as China&#8217;s First Category 1 Cardiac Stress Test Agent"},"content":{"rendered":"\n<p>China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted marketing approval for <strong>higenamine<\/strong>, a <strong>Category 1 innovative drug<\/strong> developed by <strong>Zhuhai Rundu Pharmaceutical Co., Ltd.<\/strong>, for use as a <strong>cardiac stress test agent<\/strong> in <strong>radionuclide myocardial perfusion imaging (MPI)<\/strong> to assess <strong>myocardial ischemia<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-product-classification\">Regulatory Milestone &amp; Product Classification<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Zhuhai Rundu Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td>Higenamine<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 1 innovative drug (China)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Timing<\/strong><\/td><td>April 2026 (this week)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cardiac stress testing for radionuclide myocardial perfusion imaging (MPI)<\/td><\/tr><tr><td><strong>Primary Use<\/strong><\/td><td>Assessment of myocardial ischemia<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Cardiovascular diagnostics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-profile-amp-safety-data\">Clinical Profile &amp; Safety Data<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Evidence:<\/strong> Comprehensive clinical trials demonstrated <strong>mild adverse reactions<\/strong> that rapidly resolve or disappear following drug discontinuation<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Favorable safety characteristics support routine clinical use in cardiac stress testing protocols<\/li>\n\n\n\n<li><strong>Application Scope:<\/strong> Approved for safe application in <strong>drug stress testing<\/strong> for myocardial perfusion imaging<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Suitable for patients requiring non-invasive assessment of coronary artery disease and myocardial blood flow<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-significance-amp-diagnostic-innovation\">Market Significance &amp; Diagnostic Innovation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Aspect<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Category 1 Status<\/strong><\/td><td>Represents China&#8217;s highest level of pharmaceutical innovation recognition<\/td><\/tr><tr><td><strong>Diagnostic Gap<\/strong><\/td><td>Addresses need for domestically developed cardiac stress agents with optimized safety profiles<\/td><\/tr><tr><td><strong>Clinical Workflow<\/strong><\/td><td>Enables reliable MPI procedures without exercise stress limitations<\/td><\/tr><tr><td><strong>Healthcare System<\/strong><\/td><td>Supports China&#8217;s cardiovascular disease screening and prevention initiatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Higenamine&#8217;s approval fills a critical gap in China&#8217;s diagnostic cardiology arsenal, providing clinicians with a domestically developed, innovative alternative to imported cardiac stress agents.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-strategic-positioning\">Competitive Landscape &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> As a Category 1 drug, higenamine enjoys market exclusivity and premium reimbursement positioning<\/li>\n\n\n\n<li><strong>Domestic Innovation:<\/strong> Aligns with China&#8217;s &#8220;Made in China 2025&#8221; initiative to develop indigenous high-value pharmaceutical products<\/li>\n\n\n\n<li><strong>Diagnostic Market Growth:<\/strong> Cardiovascular diagnostic imaging represents a rapidly expanding segment driven by aging population and increasing cardiovascular disease prevalence<\/li>\n\n\n\n<li><strong>Hospital Adoption:<\/strong> Favorable safety profile facilitates rapid adoption across tier-1 and tier-2 hospitals nationwide<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-outlook-amp-revenue-potential\">Commercial Outlook &amp; Revenue Potential<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> China&#8217;s MPI market exceeds 2 million procedures annually with double-digit growth rates<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> Category 1 classification supports premium pricing compared to generic alternatives<\/li>\n\n\n\n<li><strong>Reimbursement Status:<\/strong> Expected inclusion in provincial reimbursement catalogs given innovative status and clinical utility<\/li>\n\n\n\n<li><strong>Export Potential:<\/strong> Regulatory success may pave way for international filings in emerging markets seeking cost-effective diagnostic solutions<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Rundu&#8217;s commercial expectations, market adoption, and regulatory strategy for higenamine. Actual results may differ materially due to risks including market competition, reimbursement decisions, and healthcare policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[15,3948],"class_list":["post-62416","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-product-approvals","tag-rundu-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhuhai Rundu&#039;s Higenamine Receives NMPA Approval as China&#039;s First Category 1 Cardiac Stress Test Agent - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1 innovative drug developed by Zhuhai Rundu Pharmaceutical Co., Ltd., for use as a cardiac stress test agent in radionuclide myocardial perfusion imaging (MPI) to assess myocardial ischemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62416\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhuhai Rundu&#039;s Higenamine Receives NMPA Approval as China&#039;s First Category 1 Cardiac Stress Test Agent\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1 innovative drug developed by Zhuhai Rundu Pharmaceutical Co., Ltd., for use as a cardiac stress test agent in radionuclide myocardial perfusion imaging (MPI) to assess myocardial ischemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62416\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-04T15:08:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-04T15:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62416#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62416\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhuhai Rundu&#8217;s Higenamine Receives NMPA Approval as China&#8217;s First Category 1 Cardiac Stress Test Agent\",\"datePublished\":\"2026-04-04T15:08:59+00:00\",\"dateModified\":\"2026-04-04T15:09:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62416\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Product approvals\",\"Rundu Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62416#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62416\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62416\",\"name\":\"Zhuhai Rundu's Higenamine Receives NMPA Approval as China's First Category 1 Cardiac Stress Test Agent - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-04T15:08:59+00:00\",\"dateModified\":\"2026-04-04T15:09:00+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1 innovative drug developed by Zhuhai Rundu Pharmaceutical Co., Ltd., for use as a cardiac stress test agent in radionuclide myocardial perfusion imaging (MPI) to assess myocardial ischemia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62416#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62416\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62416#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhuhai Rundu&#8217;s Higenamine Receives NMPA Approval as China&#8217;s First Category 1 Cardiac Stress Test Agent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhuhai Rundu's Higenamine Receives NMPA Approval as China's First Category 1 Cardiac Stress Test Agent - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1 innovative drug developed by Zhuhai Rundu Pharmaceutical Co., Ltd., for use as a cardiac stress test agent in radionuclide myocardial perfusion imaging (MPI) to assess myocardial ischemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62416","og_locale":"en_US","og_type":"article","og_title":"Zhuhai Rundu's Higenamine Receives NMPA Approval as China's First Category 1 Cardiac Stress Test Agent","og_description":"China's National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1 innovative drug developed by Zhuhai Rundu Pharmaceutical Co., Ltd., for use as a cardiac stress test agent in radionuclide myocardial perfusion imaging (MPI) to assess myocardial ischemia.","og_url":"https:\/\/flcube.com\/?p=62416","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-04T15:08:59+00:00","article_modified_time":"2026-04-04T15:09:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62416#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62416"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhuhai Rundu&#8217;s Higenamine Receives NMPA Approval as China&#8217;s First Category 1 Cardiac Stress Test Agent","datePublished":"2026-04-04T15:08:59+00:00","dateModified":"2026-04-04T15:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62416"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Product approvals","Rundu Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62416#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62416","url":"https:\/\/flcube.com\/?p=62416","name":"Zhuhai Rundu's Higenamine Receives NMPA Approval as China's First Category 1 Cardiac Stress Test Agent - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-04T15:08:59+00:00","dateModified":"2026-04-04T15:09:00+00:00","description":"China's National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1 innovative drug developed by Zhuhai Rundu Pharmaceutical Co., Ltd., for use as a cardiac stress test agent in radionuclide myocardial perfusion imaging (MPI) to assess myocardial ischemia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62416#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62416"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62416#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhuhai Rundu&#8217;s Higenamine Receives NMPA Approval as China&#8217;s First Category 1 Cardiac Stress Test Agent"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62416"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62416\/revisions"}],"predecessor-version":[{"id":62418,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62416\/revisions\/62418"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}